TUESDAY, Oct. 30, 2018 (HealthDay News) – Three experimental Ebola vaccines trigger an immune response that lasts for more than…
TUESDAY, Oct. 30, 2018 (HealthDay News) – Three experimental Ebola vaccines trigger an immune response that lasts for more than two years against the deadly disease, researchers report.
In addition to being welcome news for the Ebola outbreak that is now spreading throughout the Democratic Republic of Congo, this success story is spurring research into the development of similar vaccines for other infectious diseases, the researchers added.
In the new study, British scientists analyzed blood samples taken from healthy volunteers who had received one of the three Ebola vaccine regimens more than two years earlier.
The results showed that all three vaccines were still producing a strong antibody response to the disease two and a half years after immunization, which is really good news, said study co-author Katie Ewer, from Oxford University in the United Kingdom.
The study was presented Monday at the American Society of Tropical Medicine and Hygiene’s annual measure ng, in new orleans.
One of the vaccines is already being used to fight the outbreak in the Congo that aid workers are struggling to contain because it unfolding in a highly dangerous conflict zone. With 1
55 deaths already confirmed since Ebola was declared in the country’s northern region in August, the fears of a cross-border epidemic are rising with new cases reported close to the Ugandan border, The Telegraph reported this week.  Meanwhile, the other two Ebola vaccines are being used as platforms for new vaccines against several other diseases with the potential to cause epidemics, including Lassa fever, Nipah virus disease, and Middle East respiratory syndrome coronavirus (MERS-CoV).
“The Ebola vaccine work that intensified after the outbreak in West Africa [2013-2016] has produced an explosion of vaccine development that could leave us much better prepared to fight other outbreaks of infectious diseases,” Ewer said in a society news release.
“Det har hjulpet policy makers og funders forstå behovet. Og at support har hjulpet med at validere nye vaccineplatforms, inklusive et som kan tilpasses for en række virale sygdomme,” Ewer ex plained.
Study co-author Dr. Matthew Snape, who is also from Oxford, said the findings “will be invaluable when deciding which strategy to use to induce long-lasting protection, for example in health care workers in areas at the ongoing risk of ebola outbreaks.”
Snape added that “Another important question is whether the persistence of this immune response can be enhanced by giving a late-booster dose of vaccine 3 to 4 years after the initial immunization, and we will study this in further work in the UK and Senegal in the coming year. “
Research presented at meetings should be considered preliminary until published in a peer-reviewed journal.
The U.S. Centers for Disease Control and Prevention have more on Ebola.